The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Kadmon Holdings, Inc. Securities Litigation
Apr 04, 2021 | Kadmon Holdings, Inc. NYSE: KDMN | Case Status: Filed
If you purchased a significant amount of shares of Kadmon Holdings, Inc. (NYSE: KDMN), you have certain options. Investors should contact us.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Kadmon Holdings, Inc.
First Identified Complaint
Rafik Tadros, et al. v. Kadmon Holdings, Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint||April 2nd, 2021|
|2||U.S. District Court Civil Docket||April 2nd, 2021|